XML 38 R27.htm IDEA: XBRL DOCUMENT v3.21.1
Stock-Based Compensation (Tables)
3 Months Ended
Mar. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Schedule of performance-based awards

​

​

​

​

​

​

​

​

​

​

​

​

​

Period Granted

​

Options Granted

​

RSUs Granted

​

Options Vested

​

RSUs Vested

​

Milestone

​

Valuation Method

(in thousands)

Q1 2019

​

200

​

300

​

169

​

260

​

(1)

​

Monte-Carlo Simulation

Q2 2019

​

—

​

188

​

—

​

81

​

(2)

​

Fair Market Value

Q3 2019

​

—

​

50

​

—

​

38

​

(1)

​

Monte-Carlo Simulation

Q1 2020

​

150

​

300

​

75

​

150

​

(1)

​

Monte-Carlo Simulation

Q1 2020

​

—

​

436

​

—

​

9

​

(3)

​

Fair Market Value

Q1 2020

​

129

​

—

​

—

​

—

​

(3)

​

Black-Scholes-Merton

Q2 2020

​

—

​

21

​

—

​

—

​

(3)

​

Fair Market Value

Q3 2020

​

10

​

—

​

10

​

—

​

(4)

​

Black-Scholes-Merton

Q3 2020

​

—

​

27

​

—

​

5

​

(3)

​

Fair Market Value

Q4 2020

​

—

​

32

​

—

​

6

​

(1)

​

Monte-Carlo Simulation

Q4 2020

​

—

​

22

​

—

​

2

​

(5)

​

Fair Market Value

Q1 2021

​

150

​

125

​

—

​

—

​

(1)

​

Monte-Carlo Simulation

Q1 2021

​

—

​

279

​

—

​

10

​

(3)

​

Fair Market Value

​

​

​

​

​

​

​

​

​

​

​

​

​

________________________________

(1) The awards will vest based on the achievement of certain values of the Company’s common stock at multiple thresholds within certain periods and are contingent upon the completion of requisite service through the date of such vesting.

​

(2) The vesting of the awards will be triggered after the end of the achievement milestone, as measured by the Company.

​

(3) The awards will vest based on achievement of a revenue target and are contingent upon the completion of requisite service through the date of such vesting.

​

(4) The awards vest based on achievement of a reimbursement target.

​
(5) The awards will vest based on achievement of certain revenue and recruiting targets.

Summary of stock option activity

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Outstanding Options

​

    

​

    

​

    

​

    

Weighted-

    

​

​

​

​

​

​

​

Weighted-

​

Average

​

​

​

​

Shares

​

​

​

Average

​

Remaining

​

Aggregate

​

​

Available for

​

Number of

​

Exercise

​

Contractual

​

Intrinsic

(in thousands, except for contractual life and exercise price)

​

Grant

​

Shares

​

Price

​

Life

​

Value

​

​

​

​

​

​

​

​

​

(in years)

​

​

Balance at December 31, 2020

 

3,197

 

6,707

​

$

11.19

​

6.04

​

$

592,468

Additional shares authorized

 

3,446

​

—

​

​

​

​

​

​

​

​

Options granted

 

(150)

 

150

​

$

119.73

​

​

​

​

​

Options exercised

 

—

 

(575)

​

$

7.95

​

​

​

​

​

Options forfeited/cancelled

 

17

 

(17)

​

$

12.64

​

​

​

​

​

RSUs granted

​

(1,180)

​

—

​

​

​

​

​

​

​

​

RSUs forfeited/cancelled

​

78

​

—

​

​

​

​

​

​

​

​

Balance at March 31, 2021

 

5,408

 

6,265

​

$

14.09

​

5.98

​

$

550,649

Exercisable at March 31, 2021

​

​

 

4,796

​

$

9.51

​

5.34

​

$

441,349

Vested and expected to vest at March 31, 2021

​

​

 

6,176

​

$

13.87

​

5.95

​

$

544,020

Restricted stock units

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Weighted-

​

​

​

​

Average

​

​

​

​

Grant Date

(in thousands, except for grant date fair value)

​

Shares

​

Fair Value

​

​

​

​

​

​

Balance at December 31, 2020

​

4,188

​

$

34.02

Granted

​

1,180

​

$

103.94

Vested

​

(632)

​

$

26.17

Cancelled/forfeited

​

(78)

​

$

35.35

Balance at March 31, 2021

​

4,658

​

$

52.38

Performance-based awards  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Schedule of assumptions used in valuation of fair value

​

​

​

​

​

​

​

​

​

March 31, 

​

2021

Risk-free interest rate

​

0.80

​

—

0.95

%

Expected dividend yield

​

​

​

​

0.00

%

Expected volatility

​

​

​

​

60

%

Expected term (years)

​

7.25

​

—

10.00

​

Employee and non-employee stock options  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Summary of stock-based compensation expenses

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three months ended March 31, 

​

​

2021

​

2020

​

    

Employee

    

Non-Employee

    

Total

    

Employee

    

Non-Employee

    

Total

​

​

(in thousands)

Cost of revenues

​

$

708

​

$

—

​

$

708

​

$

314

​

$

—

​

$

314

Research and development

​

 

3,650

​

 

224

​

 

3,874

​

 

1,682

​

 

160

​

 

1,842

Selling, general and administrative

​

 

18,604

​

 

46

​

 

18,650

​

 

5,252

​

 

9

​

 

5,261

Total

​

$

22,962

​

$

270

​

$

23,232

​

$

7,248

​

$

169

​

$

7,417

Employee stock options  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Schedule of assumptions used in valuation of fair value

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three months ended March 31, 

​

​

    

2021

    

    

2020

    

​

Expected term (years)

 

​

​

​

10.00

​

 

5.27

​

—

10.00

​

​

Expected volatility

 

​

​

​

55.33

%

 

49.94

%

—

58.53

%

​

Expected dividend rate

 

​

​

​

0

%

 

​

​

​

0

%

​

Risk-free interest rate

 

​

​

​

1.13

%

 

0.44

%

—

1.70

%

​